Literature DB >> 30762823

Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome-Associated Renal Cell Carcinoma Showing High FDG Uptake.

Zhengguang Xiao, Aisheng Dong1, Yang Wang2.   

Abstract

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome is a rare autosomal-dominant disease, characterized by the development of cutaneous and uterine leiomyomas and renal cell carcinoma (RCC). Approximately 20% to 30% of patients with HLRCC syndrome develop RCC resembling sporadic type 2 papillary RCC, which is aggressive and associated with a poor prognosis. Information on the clinical usefulness of FDG PET/CT in HLRCC syndrome-associated RCC is limited. We present a case of HLRCC syndrome-associated RCC showing high FDG uptake in both the primary RCC and retroperitoneal lymph node metastases. In addition, the patient had 2 hypermetabolic uterine leiomyomas.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30762823     DOI: 10.1097/RLU.0000000000002495

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  1 in total

1.  Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma.

Authors:  Andrew J Wiele; Devaki Shilpa Surasi; Priya Rao; Kanishka Sircar; Xiaoping Su; Tharakeswara K Bathala; Amishi Y Shah; Eric Jonasch; Vince D Cataldo; Giannicola Genovese; Jose A Karam; Christopher G Wood; Nizar M Tannir; Pavlos Msaouel
Journal:  Cancers (Basel)       Date:  2021-04-30       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.